Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2016

01-06-2016 | Breast Oncology

Optimal Surgical Management for Occult Breast Carcinoma: A Meta-analysis

Authors: Francisco Igor B. Macedo, MD, Joseph J. Eid, MD, Jeff Flynn, PhD, Michael J. Jacobs, MD, Vijay K. Mittal, MD

Published in: Annals of Surgical Oncology | Issue 6/2016

Login to get access

Abstract

Background

Occult breast cancer (OBC) represents a rare clinical entity and poses a therapeutic dilemma. Due to limited experience, no optimal treatment approaches have yet been established.

Methods

A meta-analysis was performed using MEDLINE and EMBASE databases to identify all studies investigating the surgical options for OBC: (1) axillary lymph node dissection (ALND) with radiotherapy (XRT); (2) ALND with mastectomy; and (3) ALND alone. Comparative studies including nonoperative management (observation or XRT alone) were excluded. The primary endpoints were locoregional recurrence, distant metastasis, and mortality rates.

Results

The literature search yielded 42 publications. Seven studies met the inclusion criteria comprising 241 patients. Among these patients, 94 (39 %) underwent ALND with XRT, 112 (46.5 %) underwent mastectomy, and 35 (14.5 %) underwent ALND alone. Mean follow-up was 61.8 ± 16.2 months (range 5–396 months). Locoregional recurrence (12.7 vs. 9.8 %), distant metastasis (7.2 vs. 12.7 %), and mortality rates (9.5 vs. 17.9 %) were similar between ALND with XRT and mastectomy. ALND with XRT was superior to ALND alone regarding locoregional recurrence (12.7 vs. 34.3 %, p < 0.01) and there was a trend toward improved mortality rates (9.5 vs. 31.4 %, p = 0.09).

Conclusions

There was no difference in survival outcomes between mastectomy and ALND with XRT of patients with OBC. Radiotherapy improves locoregional recurrence and, possibly mortality rates of patients undergoing ALND. Based on this meta-analysis, combined ALND and radiation therapy may appear as the optimal surgical approach in these patients.
Literature
1.
Baron PL, Moore MP, Kinne DW, et al. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg. 1990;125:210–14.CrossRefPubMed
2.
Kemeny MM, Rivera DE, Terz JJ, et al. Occult primary adenocarcinoma with axillary metastases. Am J Surg. 1986;152:43–7.CrossRefPubMed
3.
Rosen PP, Kimmel M. Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients. Hum Pathol. 1990;21:518–23.CrossRefPubMed
4.
Patel J, Nemoto T, Rosner D. Axillary lymph node metastasis from an occult breast cancer. Cancer. 1981;47(12):2923–7.CrossRefPubMed
5.
Montagna E, Bagnardi V, Rotmenez N, et al. Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. Breast Cancer Res Treat. 2011;129:867-75.CrossRefPubMed
6.
Blanchard DK, Farley DR. Retrospective study of women presenting with axillary metastases from occult breast carcinoma. World J Surg. 2004;28:535–9.CrossRefPubMed
7.
Jackson B, Scott‐Conner C, Moulder J. Axillary metastasis from occult breast carcinoma: diagnosis and management. Am Surg. 1995;61:431–4.PubMed
8.
Svastics E, Ronay P, Bodo M. Occult breast cancer presenting with axillary metastasis. Eur J Surg Oncol. 1993;19:575–80.PubMed
9.
10.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the Prisma Statement. Plos Med. 2009;6:1–6.CrossRef
11.
Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys. 2000;47(1):143–7.CrossRefPubMed
12.
Rueth NM, Black DM, Limmer AR, et al. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol. 2015;22:90–5.CrossRefPubMed
13.
Varadarajan R, Edge SB, Yu J, et al. Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology. 2006;71:456–9.CrossRefPubMed
14.
Woo SM, Son BH, Lee JW, et al. Survival outcomes of different treatment methods for the ipsilateral breast of occult breast cancer patients with axillary lymph node metastasis: a single center experience. J Breast Cancer. 2013;16(4):410–6.CrossRefPubMedPubMedCentral
15.
Vlastos G, Jean ME, Mirza AN, et al. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2000;8(5):425–31.CrossRef
16.
He M, Tang LC, Yu KD, et al. Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer. EJSO. 2012;38:1022–8.CrossRefPubMed
17.
Morris EA, Schwartz LH, Dershaw DD, et al. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology. 1997;205:437–40.CrossRefPubMed
18.
Orel SG, Weinstein SP, Schnall MD, et al. Breast MR imaging in a patient with axillary node metastases and unknown primary malignancy. Radiology. 1999;212:543–9.CrossRefPubMed
19.
De Bresser J, De Vos B, van der Ent F, et al. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. EJSO. 2010;36:114–9.CrossRefPubMed
20.
Khandelwal AK, Garguilo GA. Therapeutic options for occult breast cancer: a survey of the American Society of Breast Surgeons and review of the literature. J Am Surg. 2005;190:609–13.CrossRef
21.
Barton SR, Smith IE, Kirby AM, et al. The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. Eur J Cancer. 2011;47(14):2099–106.CrossRefPubMed
22.
van Ooijen B, Botenbal M, Henzen-Logmans SC. Axillary nodal metastases from an occult primary consistent with breast carcinomas. Br J Surg. 1993;80:1299–300.CrossRefPubMed
23.
Walker GV, Smith GL, Perkins GH, Oh JL, Woodward W, Yu TK, Hunt KK, Hoffman K, Strom EA, Buchholz TA. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010;116(17):4000–6.CrossRefPubMedPubMedCentral
24.
Trench DW, Page DL. The unknown primary presenting with axillary lymphadenopathy. In: Bland KI, Copeland EM, eds. The breast: comprehensive management of benign and malignant diseases, vol 2. 2nd edn. Philadelphia: W.B. Saunders, 1998:1447–52.
25.
Pentheroudakis G, Lazaridis G, Pavlidis N. Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat. 2010;119:1–11.CrossRefPubMed
26.
Campana F, Fourquet A, Ashby MA, et al. Presentation of axillary lymphadenopathy without detectable breast primary (T0N1b breast cancer): experience at Institut Curie. Radiother Oncol. 1989;15(4):321–5.CrossRefPubMed
27.
Ellerbroek N, Holmes F, Singletary E, et al. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer. 1990;66(7):1461–7.CrossRefPubMed
28.
Shannon C, Walsh G, Sapunar F, et al. Occult primary breast carcinoma presenting as axillary lymphadenopathy. Breast. 2002;11(5):414–8.CrossRefPubMed
Metadata
Title
Optimal Surgical Management for Occult Breast Carcinoma: A Meta-analysis
Authors
Francisco Igor B. Macedo, MD
Joseph J. Eid, MD
Jeff Flynn, PhD
Michael J. Jacobs, MD
Vijay K. Mittal, MD
Publication date
01-06-2016
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 6/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5104-8

Other articles of this Issue 6/2016

Annals of Surgical Oncology 6/2016 Go to the issue

Gynecologic Oncology

Do Patients After Reexcision Due to Involved or Close Margins Have the Same Risk of Local Recurrence as Those After One-Step Breast-Conserving Surgery?

Thoracic Oncology

Epidermal Growth Factor Receptor Mutation Status and Treatment Outcome for R0-Resected Patients with Stage 3 Non-small Cell Lung Cancer

Healthcare Policy and Outcomes

Global Curriculum in Surgical Oncology

Colorectal Cancer

What are We Going to Do with Complete Responses After Chemoradiation of Rectal Cancer?

Bone and Soft Tissue Sarcomas

Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01)

Breast Oncology

Using Multilevel Models to Explain Variation in Clinical Practice: Surgeon Volume and the Surgical Treatment of Breast Cancer